A Study to Assess the Effectiveness of Trastuzumab Deruxtecan in Chinese Breast Cancer Patients (REFRESH)
A Multi-center Prospective Observational Study to Assess the Effectiveness and Safety of Trastuzumab Deruxtecan in Chinese Breast Cancer Patients (REFRESH)
Sponsor: Daiichi Sankyo
Listed as NCT06210776, this observational or N/A phase trial focuses on Advanced Cancer and Breast Cancer and remains actively recruiting participants. Sponsored by Daiichi Sankyo, it has been updated 15 times since 2024, reflecting substantial change activity. This study contributes to the evolving evidence base for cancer treatment protocols.
Status Flow
Change History
15 versions recorded-
Feb 2026 — Present [monthly]
Recruiting
-
Dec 2025 — Feb 2026 [monthly]
Recruiting
-
Oct 2025 — Dec 2025 [monthly]
Recruiting
-
Sep 2025 — Oct 2025 [monthly]
Recruiting
-
Aug 2025 — Sep 2025 [monthly]
Recruiting
▶ Show 10 earlier versions
-
Jun 2025 — Aug 2025 [monthly]
Recruiting
-
Mar 2025 — Jun 2025 [monthly]
Recruiting
-
Feb 2025 — Mar 2025 [monthly]
Recruiting
-
Nov 2024 — Feb 2025 [monthly]
Recruiting
-
Sep 2024 — Nov 2024 [monthly]
Recruiting
-
Aug 2024 — Sep 2024 [monthly]
Recruiting
-
Jul 2024 — Aug 2024 [monthly]
Recruiting
-
May 2024 — Jul 2024 [monthly]
Recruiting
-
Mar 2024 — May 2024 [monthly]
Recruiting
-
Feb 2024 — Mar 2024 [monthly]
Recruiting
First recorded
Jan 2024
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- Daiichi Sankyo
For direct contact, visit the study record on ClinicalTrials.gov .
Study Locations
Beijing, China , Chengdu, China , Dalian, China , Foshan, China , Fuzhou, China , Guangzhou, China , Haikou, China , Hangzhou, China , Harbin, China , Hefei, China and 29 more locations